Our response to COVID-19

We're supporting people to maintain their wellbeing and manage isolation.

Lurasidone

What is lurasidone?

The treatment of bipolar disorder is complex due to the presence of varying configurations of symptoms in patients. The primary treatments for bipolar disorder are pharmacological, and often involve antipsychotic drugs such as second-generation antipsychotic, lurasidone.

What is the evidence for lurasidone as treatment for bipolar disorder?

Moderate to high quality evidence suggests significant, small to medium-sized effects of greater improvement in depression symptoms and better response to treatment with lurasidone adjunctive to mood stabilisers than with placebo adjunctive to mood stabilisers. Moderate to low quality evidence also suggests higher rates of remission with adjunctive lurasidone. There were no differences between adjunctive lurasidone and placebo in the number of adverse events, rates of switching to mania, or withdrawal from treatment for any reason.

Moderate quality evidence suggests greater improvement in depression symptoms, response to treatment, and remission with lurasidone monotherapy than with aripiprazole or ziprasidone monotherapy, with no differences between lurasidone and olanzapine or quetiapine monotherapy. There was less weight gain and somnolence with lurasidone than with ziprasidone or quetiapine; less weight gain with lurasidone than with olanzapine, but more switching to mania with lurasidone than with quetiapine.

Moderate to high quality evidence suggests no differences in depression symptoms between low (20-60 mg) and high (80-120 mg) dose lurasidone monotherapy.

July 2020

Last updated at: 12:43 am, 7th July 2020
To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.